Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Duke University Medical Center — Durham, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Oncology Specialists of Charlotte — Charlotte, North Carolina
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Associated Urologists of North Carolina — Raleigh, North Carolina
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in North Carolina: - Research Site — Raleigh, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in North Carolina: - UNC Hospitals, The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- UNC Lineberger Comprehensive Cancer Center / University of North Carolina — Chapel Hill, North Carolina
- Carolinas Medical Center (biopsy only) — Charlotte, North Carolina
- Carolinas Medical Center Investigational Drug Services — Charlotte, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
Phase 2 Recruiting NIH
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in North Carolina: - UNC Chapel Hill Hospital — Chapel Hill, North Carolina
- Duke Health - Duke Cancer Center — Durham, North Carolina
- Associated Urologists of North Carolina — Raleigh, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and pre…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05316155
Sites in North Carolina: - Levine Cancer Institute, Carolinas HealthCare System — Charlotte, North Carolina
Phase 2 Recruiting Industry
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06995677
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
- Associate Urologist of North Carolina — Raleigh, North Carolina
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Academic/Other
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety…
Sponsor: Noah Hahn, M.D.
NCT ID: NCT03317158
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in North Carolina: - Carolina Biooncology Institute — Huntersville, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Sponsor: SURGE Therapeutics
NCT ID: NCT05710848
Sites in North Carolina: - Duke Cancer Center — Durham, North Carolina
Phase 1 Recruiting Industry
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cel…
Sponsor: Eli Lilly and Company
NCT ID: NCT05614739
Sites in North Carolina: - University of North Carolina (UNC) - Chapel Hill — Chapel Hill, North Carolina
Phase 1 Recruiting Industry
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults wh…
Sponsor: Pfizer
NCT ID: NCT07206225
Sites in North Carolina: - Biorepository and Precision Pathology Center (BRPC) — Durham, North Carolina
- Duke Cancer Institute — Durham, North Carolina
- Substrate Services Core Research Support (SSCRS) — Durham, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Carolina: - AdventHealth Infusion Center Asheville — Asheville, North Carolina
- UNC Health Cancer Care Cary — Cary, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- AdventHealth Infusion Center Haywood — Clyde, North Carolina
- Durham VA Medical Center — Durham, North Carolina
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in North Carolina: - Massive Bio SYNERGY-AI site — Chapel Hill, North Carolina
- Massive Bio SYNERGY-AI site — Winston-Salem, North Carolina
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in North Carolina: - Cape Fear Valley Health System — Fayetteville, North Carolina
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in North Carolina: - UNC- Chapel Hill — Chapel Hill, North Carolina